In short
This article explores clinical trials investigating the use of MPS-102, a component of the cancer vaccine OSE2101 (Tedopi), in various cancer types. OSE2101 is being studied as an immunotherapy treatment for non-small cell lung cancer, ovarian cancer, and pancreatic cancer. The trials aim to evaluate the safety and efficacy of OSE2101 alone or in combination with other therapies.
What is MPS-102?
MPS-102 is one of the active substances in TEDOPI, an experimental cancer vaccine being developed by OSE Immunotherapeutics. TEDOPI contains 10 synthetically manufactured peptides, including MPS-102, that are designed to stimulate the immune system to fight cancer cells.
How Does MPS-102 Work?
As part of the TEDOPI vaccine, MPS-102 works by activating the body's immune system to recognize and attack cancer cells. The vaccine is specifically designed for patients with a certain genetic profile called HLA-A2 positive. This means it targets cancer cells in people whose immune systems have a specific type of molecule on their cells.
What Conditions is MPS-102 Being Studied For?
MPS-102, as part of the TEDOPI vaccine, is being studied for several types of cancer:
- Non-Small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer.
- Ovarian Cancer: Specifically for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy.
- Pancreatic Cancer: For patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Current Clinical Trials
There are several ongoing clinical trials evaluating TEDOPI (which includes MPS-102):
- ARTEMIA Study: A phase 3 trial comparing TEDOPI to docetaxel in patients with advanced non-small cell lung cancer who have developed resistance to immune checkpoint inhibitor therapy.
- TEDOVA Study: A phase 2 trial evaluating TEDOPI alone or in combination with pembrolizumab as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer.
- TEDOPAM Study: A phase 2 trial studying TEDOPI plus FOLFIRI chemotherapy as a maintenance treatment for patients with advanced pancreatic cancer.
Potential Benefits
The potential benefits of MPS-102 as part of TEDOPI include:
- Improved overall survival in patients with advanced cancers.
- Potential for better quality of life compared to standard chemotherapy.
- Possible option for patients who have developed resistance to other immunotherapy treatments.
Possible Side Effects
As TEDOPI is still in clinical trials, all potential side effects may not be known. However, common side effects of cancer vaccines can include:
- Injection site reactions (redness, swelling, pain)
- Flu-like symptoms (fever, chills, fatigue)
- Immune-related adverse events (as with other immunotherapies)
The safety profile is being closely monitored in all ongoing clinical trials.
Administration
TEDOPI, which contains MPS-102, is administered as a subcutaneous injection (an injection under the skin). The exact dosing schedule may vary depending on the specific clinical trial and condition being treated.